Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hemerophila diva

ABSTRACT: Hemerophila diva Transcriptome or Gene expression

PROVIDER: PRJNA222327 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR1005851_1.fastq.gz	Fastqsanger.gz
	SRR1005851_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Rhytiphora diva

Project description:Rhytiphora diva genome sequencing

| PRJNA341799 | ENA

ChIP-seq mapping of gH2AX, PanKcr, H3K9cr, and ENL at AsiSI-induced double-strand breaks in control and CDYL1-depleted U2OS-DIvA cells

Project description:Control and CDYL1-depleted U2OS-DIvA cells were treated with 4-hydroxy tamoxifen (4OHT) to induce multiple DNA double-strand breaks (DSBs) at defined loci in the genome via AsiSI restriction enzyme. This system was used to map the changes in lysine crotonylation (Kcr) and ENL at DSB sites in control and CDYL1-deficient cells.

2022-01-22 | E-MTAB-10550 | biostudies-arrayexpress

CTCF distribution around AsisI sites in IDHwt and IDHR132H DIvA cells

Project description:CTCF distribution around AsisI sites in IDHwt and IDHR132H DIvA cells

| PRJNA1193016 | ENA

DIVA

Project description:TEMPORAL STABILITY IN AGRICULTURAL AND URBAN FULL-SCALE ANAEROBIC DIGESTERS

| PRJEB59421 | ENA

Identifying genomic loci exhibiting chromatin decompaction upon loss of MORC2

Project description:We used the Differential Viral Integration (DIVA) technique to compare chromatin accessibility in wild-type versus MORC2 knockout HeLa cells.

2017-05-29 | GSE95457 | GEO

Tumor-infiltrating CCR2+ inflammatory monocytes counteract specific immunotherapy

Project description:We used Single-cell RNA-sequencing to analyze the composition of the tumor microenvironment of MC38mOVA tumors upon transcutaneous immunization with our immunization method DIVA.

2023-09-27 | GSE239384 | GEO

Biomarks of Resistance to Cetuximab in Colorectal Cancer

Project description:Interventions: A group:Before using cetuximab;B group:After progression of disease:no Primary outcome(s): KRAS gene sequence;NRAS gene sequence;BRAF gene sequence;PIK3CA gene sequence;EGFR gene sequence;EGFR gene copy numbers;EGFR expression;Her2 expression;c-Met expression;PTEN expression Study Design: historical control

| 2671639 | ecrin-mdr-crc

Exchange of C-Terminal Variable Sequences within Morbillivirus Nucleocapsid Protein Are Tolerated: Development and Evaluation of Two Marker (DIVA) Vaccines (Sungri/96 DIVA, Nigeria/75/1 DIVA) against PPR.

Project description:Across Africa, the Middle East, and Asia, peste des petits ruminants virus (PPRV) places a huge disease burden on agriculture, affecting, in particular, small ruminant production. The recent PPR outbreaks in Northern Africa, the European part of Turkey, and Bulgaria represent a significant threat to mainland Europe, as a source of disease. Although two safe and efficacious live attenuated vaccines (Sungri/96 and Nigeria/75/1) are available for the control of PPR, current serological tests do not enable the differentiation between naturally infected and vaccinated animals (DIVA). The vaccinated animals develop a full range of immune responses to viral proteins and, therefore, cannot be distinguished serologically from those that have recovered from a natural infection. This poses a serious problem for the post-vaccinal sero-surveillance during the ongoing PPR eradication program. Furthermore, during the latter stages of any eradication program, vaccination is only possible if the vaccine used is fully DIVA compliant. Using reverse genetics, we have developed two live attenuated PPR DIVA vaccines (Sungri/96 DIVA and Nigeria/75/1 DIVA), in which the C-terminal variable region of the PPRV N-protein has been replaced with dolphin morbillivirus (DMV). As a proof of principle, both the DIVA vaccines were evaluated in goats in pilot studies for safety and efficacy, and all the animals were clinically protected against the intranasal virulent virus challenge, similar to the parent vaccines. Furthermore, it is possible to differentiate between infected animals and vaccinated animals using two newly developed ELISAs. Therefore, these DIVA vaccines and associated tests can facilitate the sero-monitoring process and speed up the implementation of global PPR eradication through vaccination.

| S-EPMC8623000 | biostudies-literature

ChIP-seq mapping of KAT8 acetylatransferase at AsiSI-induced DNA double strand break sites

Project description:C8orf33-proficient and deficient DIvA cells were treated with 4-hydroxy tamoxifen (4OHT) to induce DNA double strand breaks (DSB) at several loci within the human genome. following 4OHT treatment cells were subject to ChIP-seq analysis for KAT8 acetyltransferase to map its enrichment at DSB sites in C8orf33 proficient deficient cells.

2025-04-10 | E-MTAB-15055 | biostudies-arrayexpress

CTCF distribution around AsisI sites in IDHwt and IDHR132H DIvA cells

Project description:IDH1 mutation impacts CTCF binding and function through methylating cytosine in the CTCF binding motif. We hypothesize that the impairment of CTCF-associated DNA repair process may be relevant to the loss of CTCF chromatin association and shifts in chromatin conformation. Chromatin immunoprecipitation-sequencing confirmed the loss of CTCF coverage in the proximity sites of AsisI sites in IDH1 mutant cells.

2025-02-12 | GSE283196 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data